Abstract: The present invention discloses compositions derived from an isolated Bacillus species, spores, or an extracellular product of Bacillus coagulans comprising a supernatant or filtrate of a culture of said Bacillus coagulans strain, suitable for topical application to the skin or mucosal membranes of a mammal, which are utilized to inhibit the growth of bacterium, yeast, fungi, virus, and combinations thereof. The present invention also discloses methods of treatment and therapeutic systems for inhibiting the growth of bacterium, yeast, fungi, virus, and combinations thereof, by topical application of therapeutic compositions which are comprised, in part, of isolated Bacillus species, spores, or an extracellular product of Bacillus coagulans comprising a supernatant or filtrate of a culture of said Bacillus coagulans strain.

Abstract: The present invention discloses compositions and methodologies for the utilization of probiotic organisms in therapeutic compositions. More specifically, the present invention relates to the utilization of one or more species or strains of lactic acid-producing bacteria, preferably strains of Bacillus coagulans, for the control of gastrointestinal tract pathogens, including antibiotic-resistant gastrointestinal tract pathogens, and their associated diseases by both a reduction in the rate of colonization and the severity of the deleterious physiological effects of the colonization of the antibiotic-resistant pathogen. In addition, the present invention relates to the utilization of therapeutic compounds comprised of lactic acid-producing bacteria and anti-microbial agents such as antibiotics, anti-fungal compounds, anti-yeast compounds, or anti-viral compounds.

Abstract: The present invention is directed to methods for producing and selecting new mutant strains of B. fragilis that constitutively express a particular capsular polysaccharide or only selected capsular polysaccharides; compositions directed to the new mutant strains of B. fragilis that constitutively express a particular capsular polysaccharide or only selected capsular polysaccharides; improved methods for purification of individual capsular polysaccharides; and compositions directed to new res02 and inv19 genes and their gene products. Significantly, the present invention provides methods and compositions for overexpressing and purifying immunomodulatory capsular polysaccharide A (PSA) in high yield.

Abstract: A method of treating cancer in a subject in need thereof comprises administering said subject reserpine, yohimbine, an analog thereof, or a pharmaceutically acceptable salt or prodrug thereof, in an amount effective to treat the cancer. Compounds and compositions useful for carrying out the method are also described.

Abstract: The present invention relates to compositions that can improve biological activity or can increase population density of natural or beneficial microorganisms on surfaces. By proper use of the compositions, the present invention provides uses of protecting plants from plant pathogen, harmful insects or weedy plants or of promoting plant growth. By proper use of the compositions in the present invention, biological activity or population density of natural or beneficial microorganisms can be increased and the improved biological activity or population density of the microorganisms can protect plants from harmful organisms including plant pathogens, harmful insects or weedy plants or can promote plant growth.

Abstract: This invention relates to a method of lowering feces toxin levels and treating digestive disorders (e.g., Irritable Bowel Syndrome or diarrhea) with a composition containing a live beneficial bacterium, a prebiotic, or both. This method includes first identifying a subject in need thereof and then administering to the subject an effective amount of the composition. Also within the scope of this invention is a composition including both a live beneficial bacterium and a prebiotic.

Abstract: Liquid-based phamaceutical and/or veterinary and/or nutraceutical compositions comprising non pathogenic sporogenic bacteria, component SP), and the following components: O) from 0.001 to 95% by weight of one or more oils selected from esters of C4-C32 acids, C4-C32, S) from 0 to 90% by weight of one or more amphiphilic compounds, selected from surfactants, polymers forming organized structures such as aggregates, micelles, liquid crystals, vesicles, in the liquid in which they are solubilized, AD) from 0 to 60% by weight of one or more additive compounds selected from modifiers of the water and/or oil polarity, modifiers of the film curvature of component S), ?co-surfactants, PA) from 0.001 to 70% of one or more compounds selected from food supplements and pharmaceutical and/or veterinary active principles, W) from 0.1 to 99.

Abstract: Fungicidal mixtures, comprising 1) a fungicidal strain (I) selected from a) the Bacillus substilis strain with NRRL Accession No. B-21661, and b) the Bacillus pumilus strain with NRRL Accession No. B-30087, or a mutant of these strains having all the identifying characteristics of the respective strain, or a metabolite produced by the respective strain that exhibits activity against plant pathogenic fungi, and 2) at least one chemical compound II, selected from the active compound groups A) to F): A) azoles; B) strobilurins; C) carboxamides; D) heterocyclic compounds; E) carbamates; F) other fungicides; in a synergistically effective amount, methods for controlling harmful fungi using compositions of components 1) and 2), the use of a component 1) with a component 2) for preparing such compositions, and also fungicidal agents and seed comprising such compositions.

Abstract: Bacillus strains that inhibit pathogenic swine E. coli and/or improve performance are provided. Inhibition of pathogenic swine E. coli decreases E. coli disease. At least one strain enhanced swine performance by improving average daily gain, feed efficiency, and feed intake. Preferred Bacillus strains are of species that are included on the GRAS list. Bacillus species are sporeformers and therefore are highly stable and can be fed to swine.

Abstract: The present invention relates to methods of treating a cancerous tumor in a subject comprising administering to the subject an effective amount of 3-bromopyruvate. The 3-bromopyruvate may be administered intraarterially directly to a tumor as a continuous intraarterial infusion. The present invention also relates to methods for identifying agents that inhibit type II hexokinase activity.

Abstract: An antibiotic formulation including penicillinase resistant penicillin, cefixime trihydrate, lactobacillus and pharmaceutically acceptable excipients. The penicillinase resistant penicillin is in two forms, sustained release and immediate release.

Abstract: The invention relates generally to digestive disorders, and in particular to methods for treating irritable bowel syndrome by increasing carbohydrate absorption by administering a composition containing a Bacillus coagulans bacterium.

Abstract: The invention provides compositions, kits, and methods for providing or restoring beneficial bacteria to a subject. The compositions and kits optionally include food or nutrients to promote growth and proliferation of the bacteria in the subject or an antimicrobial agent to reduce the presence of undesirable or pathogenic microbes in the subject.

Abstract: A probiotic composition including the bacilli (1) Bacillus subtilis, (2) Bacillus coagulans, and (3) Enterococcus faecium. The composition may further include a carrier medium, such as fructo-oligo-saccharides (FOS), as incorporated in a dose form such as a pill, capsule, powder or sachet. The compositions of the invention may be usefully employed as health or nutritional supplements, food additives, or therapeutic agents for combating a wide variety of physiological disorders, such as irritable bowel syndrome, autism, and fibromyalgia.

Abstract: A carbohydrate modifying formulation that modulates the rate of sugar absorption and/or metabolism in a subject to whom the formulation is administered. In one embodiment, the formulation comprises an active soluble fiber, one or more polyphenolic compounds, an aqueous diluent, and sugar. In another embodiment, the formulation is a dry powder that comprises an active soluble fiber, antioxidant containing botanical extracts, crystalline fructose, a probiotic, vitamins and minerals.

Abstract: Described are strains including Enterococcus faecium strain 8G-1 (NRRL B-50173), Enterococcus faecium strain 8G-73 (NRRL B-50172), Bacillus pumilus strain 8G-134 (NRRL B-50174) and strains having all of the identifying characteristics of each of these strains. One or more of the strains can be used to treat or prevent acidosis. They can also be used to improve other measures of ruminant health and/or performance. Methods of using the strains, alone and in combination, are described. Methods of making the strains are also provided.

Abstract: A method of treating autism using a probiotic composition including the bacilli (1) Bacillus subtilis, (2) Bacillus coagulans, and (3) Enterococcus faecium. The composition may further include a carrier medium, such as fructo-oligo-saccharides (FOS), as incorporated in a dose form such as a pill, capsule, powder or sachet. The compositions of the invention may be usefully employed as health or nutritional supplements, food additives, or therapeutic agents for combating a wide variety of physiological disorders.

Abstract: An isolated Bacillus amyloliquefaciens Ba-BPD1 having an Accession No. of DSM 21836 is provided. This novel strain has unique 16S ribosomal RNA sequenced as SEQ ID NO:1 and produces amylase, protease, cellulase and lipase, fibrinolytic enzyme to show their biodegradation capacities. Further, B. amyloliquefaciens Ba-BPD1 produces the antibiotic substances, such as iturin, fengycin and surfactin, and has antimicrobial capacity for inhibiting the fungal or bacterial growth. In conclusion, the novel strain of Bacillus amyloliquefaciens Ba-BPD1 and its products can be applied in agriculture, wastewater treatment, food industry and chemical industry.

Abstract: Disclosed herein are compositions for the treatment of a disease in an animal including yeast extract of Saccharomyces cerevisiae, Bacillus licheniformis or Bacillus subtilis spores, and a carrier. Also included are animal feed compositions including the composition for the prevention, control and/or treatment of a disease in an animal and an animal's food/feed. The compositions are useful to prevent, control, and treat diseases such as necrotic enteritis in poultry when used in combination with an anticoccidal ionophore or coccidiosis vaccine.

Abstract: A method of treating irritable bowel syndrome using a probiotic composition including the bacilli (1) Bacillus subtilis, (2) Bacillus coagulans, and (3) Enterococcus faecium. The composition may further include a carrier medium, such as fructo-oligo-saccharides (FOS), as incorporated in a dose form such as a pill, capsule, powder or sachet. The compositions of the invention may be usefully employed as health or nutritional supplements, food additives, or therapeutic agents for combating a wide variety of physiological disorders.

Abstract: The invention describes the use of a microbial preparation of one or more bacteria, for example of the genus Bacillus in the manufacture of a formulation as a medicament for the treatment and prevention of infestation of sucking lice from the order Phthiraptera, Anoplura, Rhynchophthirina and/or Pediculidae. The medicament can be applied to plumage, pelage or hair to control sucking lice.

Abstract: The present invention relates to the treatment of prostate cancer. Methods and compositions comprising recombinant BCG are provided for eliciting potent immune responses against prostate specific antigens that are effective for treatment of prostate cancer and metastatic disease.

Abstract: The invention relates to aqueous aerosol preparations for inhalation, containing therapeutically active micro-organisms or parts of micro-organisms as the active ingredient.

Abstract: Compositions containing a lactic acid-producing bacterial strain, e.g., Bacillus coagulans for inhibition of pathogenic bacterial infections. Spores or extracellular products produced by the bacterial strains are also useful as inhibitory agents.

Abstract: The present invention discloses compositions and methodologies for the utilization of probiotic organisms in therapeutic compositions. More specifically, the present invention relates to the utilization of one or more species or strains of lactic acid-producing bacteria, preferably strains of Bacillus coagulans, for the control of gastrointestinal tract pathogens, including antibiotic-resistant gastrointestinal tract pathogens, and their associated diseases by both a reduction in the rate of colonization and the severity of the deleterious physiological effects of the colonization of the antibiotic-resistant pathogen. In addition, the present invention relates to the utilization of therapeutic compounds comprised of lactic acid-producing bacteria and anti-microbial agents such as antibiotics, anti-fungal compounds, anti-yeast compounds, or anti-viral compounds.

Abstract: The present invention relates to the use of isolated polypeptides as a coccidiostat and/or as a histomonastat. An example of a polypeptide of the invention is the so-called L12 protein from Bacillus licheniformis ATCC 14580. The invention furthermore relates to the probiotic use of strains of Bacillus, which produce proteins related to L12.

Abstract: Acetyl esterase producing bacterial strains or functional mutants thereof and methods of using acetyl esterase producing bacterial strains as forage additives are disclosed.

Abstract: The invention relates generally to digestive disorders, and in particular to methods for treating irritable bowel syndrome by increasing carbohydrate absorption by administering a composition containing a Bacillus coagulans bacterium.

Abstract: The present invention relates to a composition for the administration of biologically active substances in a gynaecologic and rectal ambit, as well as the uses of said composition. Said composition presents particularly favourable technological and stability characteristics of the end product, above all with regard to the viscosity after the dissolution/resuspension of the same in a hydrophilic liquid medium which allows a better adhesion and a direct contact from bacteria to the treated mucosae. Said composition includes a specific viscosizing agent selected from the group of the gums, which can play an important prebiotic function by contributing in a significant way to the correct growth and colonization of the probiotic culture, thus forming a perfect symbiotic system.

Abstract: Methods of inducing systemic acquired resistance to infection in a plant by applying a composition comprising a Bacillus control agent to said plant wherein said plant is capable of producing defense proteins.

Abstract: The invention features methods for increasing or maintaining the number of functional cells of a predetermined type in a mammal (e.g., a human patient), for example, the insulin producing cells of the pancreas, liver cells, spleen cells, or bone cells, that has injured or damaged cells of the predetermined type or is deficient in cells of the predetermined type.

Abstract: The present invention is directed to methods for producing and selecting novel mutant strains of B. fragilis that constitutively express a particular capsular polysaccharide or only selected capsular polysaccharides; compositions directed to the novel mutant strains of B. fragilis that constitutively express a particular capsular polysaccharide or only selected capsular polysaccharides; improved methods for purification of individual capsular polysaccharides; and compositions directed to novel res02 and inv19 genes and their gene products. Significantly, the present invention provides methods and compositions for overexpressing and purifying immunomodulatory capsular polysaccharide A (PSA) in high yield.

Abstract: The present invention relates to methods for a long-term and sustained release of flavonoids, in particular rhamnose-containing flavonoids, and for prolonging the uptake of said flavonoids in the gastro-intestinal tract. It further relates to compositions comprising said flavonoid and ?-rhamnosidase. It also encompasses compositions comprising hesperidin and hesperetin-7-glucoside.

Abstract: This invention provides combinations of at least one biological control agent and at least one nematicide to enhance plant protection against pests and pathogens.

Abstract: The present invention relates to Bacillus amyloliquefaciens strain NRRL B-50154 and methods and compositions for preventing and/or reducing biofilm formation on surfaces and/or planktonic proliferation in aqueous environments, especially in domestic/household and industrial settings. The present invention also relates to deodorizing liquid compositions which are designed to be applied in the areas of pet care, toilet care, carpet care, and garbage collections or processes, management of industrial wastes, including sludge processing, landfill and composting, and odor control of livestock production processes and other organic wastes.

Abstract: Brevibacillus choshinensis is characterized in that its extracellular proteolytic activity is extremely low and its protein secretion productivity is excellent, but it is desired that not only the extracellular proteolytic activity of the strain is further reduced but also the intracellular proteolytic activity thereof is further reduced. When Brevibacillus choshinensis is used as a host for the production of protein pharmaceuticals and the like, it is also desired that it does not form spores and is readily sterilized. The above problems have been solved by inactivating the sporulation-associated gene thereof and by cloning and inactivating the extracellular and intracellular protease genes thereof.

Abstract: The present invention relates to the use of isolated polypeptides as coccidiostat and/or histomonastat. An example of a polypeptide of the invention is the so-called L12 protein from Bacillus licheniformis ATCC 14580.

Abstract: The present invention relates to Bacillus velezensis strain NRRL B 50150 and methods and compositions for preventing and/or reducing biofilm formation on surfaces and/or planktonic proliferation in aqueous environments, especially in domestic/household and industrial settings. The present invention also relates to deodorizing liquid compositions which are designed to be applied in the areas of pet care, toilet care, carpet care, and garbage collections or processes, management of industrial wastes, including sludge processing, landfill and composting, and odor control of livestock production processes and other organic wastes.

Abstract: The invention relates to a new bacterial strain belonging to the genus Brevibacillus laterosporus deposited at the NCIMB Ltd. Aberdeen, UK and to its derivatives. The bacterium and its derivatives have insecticidal activity and constitute the active principle of compositions and feeding baits used for biological control of Dipters, Nematocers and Brachycerus (flies, mosquitos, horseflies and midges) and especially against the species Musca domestica. Therefore, according to a further aspect, the invention relates to a method for biological control of insects belonging to the order Dipters. The active principle has activity against Nematocers and Brachycerus (flies, mosquitos, horseflies and midges) and especially against the species Musca domestica.

Abstract: A device and a method for rapidly determining the effectiveness of sterilization or disinfection processes are provided. The method involves contacting a biological indicator containing a known number of live spores to a sterilization or disinfection process. When the spores are killed, the minerals in the spores are released. Water is contacted with the dead spores to form an aqueous solution. A parameter related to the concentration of a mineral in the aqueous solution is measured. The effectiveness of the germicidal process is determined from the parameter and the initial number of spores in the biological indicator. Measuring the parameter by measuring the conductivity of the aqueous solution is particularly effective and sensitive.

Abstract: A synergistic antibacterial formulation and a method of making the same is disclosed. The composition contains Cefixime Trihydrate+Cloxacillin Sodium+Lactobacillus sporogenes spores. The Cloxacillin sodium is in two forms in a sustained release and an immediate release form. A drug delivery system for providing the formulation is provided.

Abstract: Disclosed is a composition for administration to a human or animal subject, the composition containing spores of Bacillus subtilis in an amount effective to stimulate immune responsiveness in the subject. The spores have an adjuvant, immunomodulatory, immune potentiation, or dendritic cell maturation effect, or a combination thereof Also disclosed is a method of boosting an immune response in an animal subject by administering B. subtilis spores to an animal or human subject. Further disclosed is a vaccine containing B. subtilis spores, in the presence or absence of an antigen.

Abstract: The present invention is directed to compositions comprising one or more species of probiotic bacteria, optionally in combination with one or more prebiotics, to methods of preventing and treating respiratory infections in animals by employing such compositions, and to methods of preparing the same.

Abstract: Disclosed are methods of administering at least two Bacillus strains to a pig, such as female breeding stock, nursery pigs, or other pigs. The Bacillus strains inhibit Clostridium in litters borne to the pig. The Bacillus strains also are useful when administered to herds lacking symptoms of Clostridium infection. Administration of the Bacillus strains improves performance of female breeding stock and in piglets borne by the female breeding stock.

Abstract: The present invention relates to a novel microorganism Bacillus amyloliquefaciens KTGB0202 and a method for controlling plant pathogens using the same. More particularly, the present invention relates to a novel microorganism Bacillus amyloliquefaciens KTGB0202 (accession number: KCTC 10564BP) bacterium which has an excellent control effect against crop powdery mildew and a broad spectrum of antifungal activity against plant pathogenic fungi and inhibits tobacco mosaic virus infection, as well as an eco-friendly bacterial culture broth for controlling powdery mildew, which contains the same. Also, the present invention relates to antifungal substance KTGB0202AFO1 obtained by extraction and purification from the Bacillus amyloliquefaciens KTGB0202 bacteria. The inventive Bacillus amyloliquefaciens KTGB0202 bacteria have a broad spectrum of antifungal activity, and are excellent in activity continuance and used for controlling various plant pathogens, including powdery mildew.

Abstract: The composition described is to be applied topically to the skin to treat acne and other skin disorders caused in part or wholly by bacterial or mycosal infections. Acne and related skin disorders have complex causes. This formula contains compounds, including an effective amount Bacillus amyloliquefaciens (Bam), that have distinct functions in reducing the sebum on the surface of the skin and inhibiting the proliferation of microbes and fungi where the skin has been wounded or in sebaceous pores. This formula also aims to increase the rate of healing of scars caused by acne by inhibiting opportunistic bacteria from colonizing the wound, while ensuring that healthier skin remains protected from such parasitic bacteria.

Abstract: Three choline utilizing strains of microorganisms isolated from the anthers of wheat, Aureobasidium pullulans strain AS 55.2, Arthrobacter species strain OH 221.3, and Pseudomonas species strain AS 64.4, are superior antagonists of F. graminearum. These microorganisms are effective for suppression and control of FHB in cereals, particularly in wheat and barley.

Abstract: The disclosure relates to a solid glass matrix of polysaccharide, saccharides and polyols as delivery vehicle for preservation and post gastric administration of a probiotic. The delivery vehicle is capable of releasing the probiotic at their site of action. The present invention further includes methods of making and using the solid glass matrix delivery vehicle of the invention.

Abstract: The invention relates to a cosmetic and/or dermatological topical composition, of particular use for the prevention al and/or treatment of sensitive and/or dry skin, comprising an effective amount of at least one particularly probiotic microorganism and/or a fraction or metabolite thereof in combination with an effective amount of at least one polyunsaturated fatty acid and/or polyunsaturated fatty acid ester and/or a salt or derivative thereof in a physiologically-acceptable vehicle.

Abstract: A solution for the cleaning of toothbrushes consisting of a watery solution with a mixture of non-pathogenic gram-positive bacteria of the Bacillus genus, whereby the enzymatic action decomposes any food particles remaining between the hairs of a toothbrush, and a receptacle, possibly with several compartments, for the introduction of the solution, in which the toothbrush is submerged.